+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Epilepsy Drug Market by Product Type, Distribution Channel - Global Forecast 2025-2030- Product Image
Epilepsy Drug Market by Product Type, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Epilepsy Drug Market by Product Type, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5456899
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Epilepsy Drug Market grew from USD 4.55 billion in 2023 to USD 4.87 billion in 2024. It is expected to continue growing at a CAGR of 7.09%, reaching USD 7.35 billion by 2030.

The epilepsy drug market is defined by the scope of medications designed to manage and treat seizures associated with epilepsy. The necessity for these drugs is driven by the high prevalence of epilepsy, which affects approximately 50 million people globally. These medications are crucial for patients as they help in controlling seizures, improving quality of life, and reducing the risk of injury related to seizure episodes. The application scope includes monotherapy and adjunctive therapy, with differing requirements for various age groups, types of epilepsy, and severity levels. The end-use scope spans hospitals, clinics, online pharmacies, and retail pharmacies, showcasing a broad market presence.

Key insights into growth factors include ongoing advancements in drug formulations, increasing awareness and diagnosis rates, and supportive government policies. Developing economies offer potential opportunities due to unmet needs and increasing healthcare investments. Innovations in personalized medicine and novel drug delivery systems, including sustained-release formulations and targeted therapies, present promising avenues for business growth. However, limitations such as high costs, regulatory hurdles, and side effects of current medications present significant challenges. Additionally, market growth is hampered by the availability of alternative therapies like dietary interventions and neural stimulation.

The nature of the epilepsy drug market is highly competitive and research-driven. There is a substantial opportunity in investing in R&D for drugs with improved efficacy and reduced side effects. The integration of artificial intelligence in clinical trials could streamline development processes, while collaborations with biotech firms could accelerate innovation. Strategic recommendations include focusing on emerging markets, enhancing patient adherence through digital health solutions, and expanding product portfolios via collaborations. Maintaining a patient-centric approach while leveraging technological advancements can help companies navigate the complexities of this market and capture emerging opportunities effectively.

Understanding Market Dynamics in the Epilepsy Drug Market

The Epilepsy Drug Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing prevalences of epilepsy
    • Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
    • Rising investment and support from the government
  • Market Restraints
    • Lack of infrastructure and scarcity of treatment for epilepsy
  • Market Opportunities
    • Rising drug approvals of anticonvulsant drugs from regulatory bodies
    • Penetration of collaboration and product launch activities
  • Market Challenges
    • Side effects associated with the drugs

Exploring Porter’s Five Forces for the Epilepsy Drug Market

Porter’s Five Forces framework further strengthens the insights of the Epilepsy Drug Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Epilepsy Drug Market

External macro-environmental factors deeply influence the performance of the Epilepsy Drug Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Epilepsy Drug Market

The Epilepsy Drug Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Epilepsy Drug Market

The Epilepsy Drug Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Epilepsy Drug Market

The Epilepsy Drug Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Epilepsy Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Densa Pharmaceuticals Pvt. Ltd., Eisai Co., Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Micro Labs Ltd., Novartis International AG, Pfizer Inc., Psychotropics India Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Epilepsy Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product Type
    • First-Generation Drugs
      • Ethosuximide
      • Oxcarbazepine
      • Phenytoin
    • Second-Generation Drugs
      • Felbamate
      • Lamotrigine
      • Topiramate
    • Third-Generation Drugs
      • Eslicarbazepine Acetate
      • Lacosamide
      • Ralfinamide
  • Distribution Channel
    • Hospital Pharmacy
    • Pharmacy Stores
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalences of epilepsy
5.1.1.2. Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
5.1.1.3. Rising investment and support from the government
5.1.2. Restraints
5.1.2.1. Lack of infrastructure and scarcity of treatment for epilepsy
5.1.3. Opportunities
5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
5.1.3.2. Penetration of collaboration and product launch activities
5.1.4. Challenges
5.1.4.1. Side effects associated with the drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Epilepsy Drug Market, by Product Type
6.1. Introduction
6.2. First-Generation Drugs
6.2.1. Ethosuximide
6.2.2. Oxcarbazepine
6.2.3. Phenytoin
6.3. Second-Generation Drugs
6.3.1. Felbamate
6.3.2. Lamotrigine
6.3.3. Topiramate
6.4. Third-Generation Drugs
6.4.1. Eslicarbazepine Acetate
6.4.2. Lacosamide
6.4.3. Ralfinamide
7. Epilepsy Drug Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Pharmacy Stores
8. Americas Epilepsy Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Epilepsy Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Epilepsy Drug Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. EPILEPSY DRUG MARKET RESEARCH PROCESS
FIGURE 2. EPILEPSY DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 9. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. EPILEPSY DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. EPILEPSY DRUG MARKET DYNAMICS
TABLE 7. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL EPILEPSY DRUG MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL EPILEPSY DRUG MARKET SIZE, BY OXCARBAZEPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PHENYTOIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FELBAMATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL EPILEPSY DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL EPILEPSY DRUG MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL EPILEPSY DRUG MARKET SIZE, BY ESLICARBAZEPINE ACETATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL EPILEPSY DRUG MARKET SIZE, BY LACOSAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL EPILEPSY DRUG MARKET SIZE, BY RALFINAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PHARMACY STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. CANADA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 43. CANADA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 44. CANADA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 45. CANADA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 46. CANADA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. MEXICO EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 49. MEXICO EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 50. MEXICO EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 51. MEXICO EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. CHINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. CHINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 71. CHINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 72. CHINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 73. CHINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. INDIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. INDIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 76. INDIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 77. INDIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 78. INDIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. JAPAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. JAPAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 86. JAPAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 87. JAPAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 88. JAPAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. THAILAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. THAILAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 116. THAILAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 117. THAILAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 118. THAILAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 130. DENMARK EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. DENMARK EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 132. DENMARK EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 133. DENMARK EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 134. DENMARK EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. EGYPT EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. EGYPT EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 137. EGYPT EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 138. EGYPT EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 139. EGYPT EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. FINLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. FINLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 142. FINLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 143. FINLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 144. FINLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. FRANCE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. GERMANY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. ITALY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 161. ITALY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 162. ITALY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 163. ITALY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 164. ITALY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. NORWAY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. NORWAY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 177. NORWAY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 178. NORWAY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 179. NORWAY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. POLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. POLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 182. POLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 183. POLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 184. POLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. QATAR EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. QATAR EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 187. QATAR EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 188. QATAR EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 189. QATAR EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SPAIN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. SPAIN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 207. SPAIN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 208. SPAIN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 209. SPAIN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. TURKEY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. TURKEY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 222. TURKEY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2023
TABLE 236. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Epilepsy Drug Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Densa Pharmaceuticals Pvt. Ltd.
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Micro Labs Ltd.
  • Novartis International AG
  • Pfizer Inc.
  • Psychotropics India Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • UCB S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 4.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.35 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Epilepsy Drugs Market Size, Share & Trends Analysis Report by Product (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), Region, and Segment Forecasts, 2023-2030 - Product Image

Epilepsy Drugs Market Size, Share & Trends Analysis Report by Product (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), Region, and Segment Forecasts, 2023-2030

  • Report
  • 91 Pages
  • Global
From
Epilepsy Drugs - Global Strategic Business Report - Product Image

Epilepsy Drugs - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis - Product Image

Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis

  • Report
  • 250 Pages
  • Global
From
Childhood Absence Epilepsy Treatment Market by Drug, Disease Type - Global Forecast 2025-2030 - Product Image

Childhood Absence Epilepsy Treatment Market by Drug, Disease Type - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2024-2032 - Product Image

Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2024-2032

  • Report
  • 145 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.